Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| C4 Therapeutics, Inc.CCCC · Entity 5503 | Director | June 22, 2022 | June 23, 2022 |
| Korro Bio, Inc.FREQ · Entity 6388 | Director | June 21, 2022 | June 23, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
C4 Therapeutics, Inc.
Report date June 22, 2022 · Filed June 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.06 · Expires 2032-06-21 | Direct | 23,500 |
Reported balance
After 2022-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-22 · Grant · Acquired 23,500 · Balance 23,500 F1: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 22, 2023 and (ii) the next annual meeting of the Issuer's stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 22, 2023 and (ii) the next annual meeting of the Issuer's stockholders.
Korro Bio, Inc.
Report date June 21, 2022 · Filed June 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.17 · Expires 2032-06-20 | Direct | 14,846 |
Reported balance
After 2022-06-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-21 · Grant · Acquired 14,846 · Balance 14,846 F1: The option vests in full on the earlier of June 21, 2023 or the day immediately prior to the company's 2023 annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the earlier of June 21, 2023 or the day immediately prior to the company's 2023 annual meeting of shareholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2022 Filed Jun 23, 2022 16:15 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 23,500 | $0.00 Strike: $6.06 | $0.00 |
DisclosureSEC source: 0001209191-22-038863 · doc4.xml · derivative · entry 1 COHEN MARC A · CIK 0001132945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2032-06-21 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 22, 2023 and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 16:19 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 14,846 | $0.00 Strike: $1.17 | $0.00 |
DisclosureSEC source: 0001127602-22-018038 · form4.xml · derivative · entry 1 COHEN MARC A · CIK 0001132945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,846 Underlying: Common Stock · 14,846 shares Expires 2032-06-20 F1 · derivative.exercise_date: The option vests in full on the earlier of June 21, 2023 or the day immediately prior to the company's 2023 annual meeting of shareholders. Read SEC document |
| January 04, 2022 Filed Jan 18, 2022 16:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 657 | $31.58 | $20,748.06 |
DisclosureSEC source: 0001209191-22-003503 · doc4.xml · nonDerivative · entry 1 COHEN MARC A · CIK 0001132945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,118 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on January 4, 2022. Read SEC document |
| October 04, 2021 Filed Oct 5, 2021 16:55 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 461 | $44.99 | $20,740.39 |
DisclosureSEC source: 0001209191-21-059522 · doc4.xml · nonDerivative · entry 1 COHEN MARC A · CIK 0001132945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 461 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 4, 2021. F3 · balance_after: This amount has been adjusted to reflect 6,641 shares previously transferred from the Reporting Person to the Marc Andrew Cohen Revocable Trust. Read SEC document |
| July 02, 2021 Filed Jul 7, 2021 16:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 522 | $39.72 | $20,733.84 |
DisclosureSEC source: 0001209191-21-045807 · doc4.xml · nonDerivative · entry 1 COHEN MARC A · CIK 0001132945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,641 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 2, 2021. F3 · balance_after: This amount has been adjusted to reflect 92,817 shares previously transferred from the Reporting Person to the Marc Andrew Cohen Revocable Trust. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 16:26 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 14,846 | $0.00 Strike: $10.14 | $0.00 |
DisclosureSEC source: 0001127602-21-020399 · form4.xml · derivative · entry 1 COHEN MARC A · CIK 0001132945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,846 Underlying: Common Stock · 14,846 shares Expires 2031-06-16 F1 · derivative.exercise_date: The option vests in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 16:15 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 23,500 | $0.00 Strike: $37.66 | $0.00 |
DisclosureSEC source: 0001209191-21-041423 · doc4.xml · derivative · entry 1 COHEN MARC A · CIK 0001132945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2031-06-14 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 15, 2022 and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 14, 2021 Filed Jun 14, 2021 17:16 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | OtherCommon Stock | 22,598 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040278 · doc4.xml · nonDerivative · entry 2 COHEN MARC A · CIK 0001132945 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,874,805 F1 · kind: Represents the receipt of shares by the Reporting Person pursuant to pro rata distributions-in-kind, without consideration, of shares of the company's common stock effected on June 14, 2021 by Cobro Ventures Opportunity Fund, L.P. ("Cobro Ventures") to the partners of Cobro Ventures and by its general partner, Cobro Ventures Fund GP, LLC. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.nature: Shares held by Reporting Person as trustee of the Marc Andrew Cohen Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| June 14, 2021 Filed Jun 14, 2021 17:16 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | OtherCommon Stock | 92,817 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040278 · doc4.xml · nonDerivative · entry 1 COHEN MARC A · CIK 0001132945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,936 F1 · kind: Represents the receipt of shares by the Reporting Person pursuant to pro rata distributions-in-kind, without consideration, of shares of the company's common stock effected on June 14, 2021 by Cobro Ventures Opportunity Fund, L.P. ("Cobro Ventures") to the partners of Cobro Ventures and by its general partner, Cobro Ventures Fund GP, LLC. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 16:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 553 | $37.51 | $20,743.03 |
DisclosureSEC source: 0001209191-21-025661 · doc4.xml · nonDerivative · entry 1 COHEN MARC A · CIK 0001132945 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,119 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 5, 2021. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 16:15 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionStock Option (Right to Buy) · Derivative | 536 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001209191-21-012339 · doc4.xml · derivative · entry 4 COHEN MARC A · CIK 0001132945 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,209 Underlying: Common Stock · 536 shares Expires 2026-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents underlying unexercised stock options that were granted on July 13, 2016. The terms of the original grant provide that 12.5% of this option vested and became exercisable on December 31, 2016, with the remainder vesting in 28 equal quarterly installments thereafter, subject to the Reporting Person's continuous service through each such date. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 16:15 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | Exercise / conversionCommon Stock | 536 | $2.11 | $1,130.96 |
DisclosureSEC source: 0001209191-21-012339 · doc4.xml · nonDerivative · entry 1 COHEN MARC A · CIK 0001132945 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,566 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 06, 2020 Filed Oct 6, 2020 21:28 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | ConversionSeries B Preferred Stock · Derivative | 20,952,403 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027697 · doc4.xml · derivative · entry 7 COHEN MARC A · CIK 0001132945 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Cobro Ventures Opportunity Fund, L.P. Disclosed balance after: 0 Underlying: Common Stock · 2,484,425 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F3 · ownership.nature: Shares held by Cobro Ventures Opportunity Fund, L.P. ("Cobro Ventures"). The Reporting Person serves as a manager of Cobro Opportunity Fund GP, LLC, the general partner of Cobro Ventures, and may be deemed to exercise voting and investment power over the shares held by Cobro Ventures. The Reporting Person disclaims beneficial ownership of the shares held by Cobro Ventures except to the extent of his pecuniary interest therein. Read SEC document |
| October 06, 2020 Filed Oct 6, 2020 21:28 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | ConversionSeries A Preferred Stock · Derivative | 12,500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027697 · doc4.xml · derivative · entry 6 COHEN MARC A · CIK 0001132945 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,482,183 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F2 · ownership.nature: Shares held by Reporting Person as trustee of the Marc Andrew Cohen Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| October 06, 2020 Filed Oct 6, 2020 21:28 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | ConversionSeries Seed Preferred Stock · Derivative | 2,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027697 · doc4.xml · derivative · entry 5 COHEN MARC A · CIK 0001132945 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 237,149 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F2 · ownership.nature: Shares held by Reporting Person as trustee of the Marc Andrew Cohen Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| October 06, 2020 Filed Oct 6, 2020 21:28 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | PurchaseCommon Stock | 5,030 | $19.00 | $95,570.00 |
DisclosureSEC source: 0000899243-20-027697 · doc4.xml · nonDerivative · entry 4 COHEN MARC A · CIK 0001132945 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,030 Read SEC document |
| October 06, 2020 Filed Oct 6, 2020 21:28 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | ConversionCommon Stock | 2,484,425 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-027697 · doc4.xml · nonDerivative · entry 3 COHEN MARC A · CIK 0001132945 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Cobro Ventures Opportunity Fund, L.P. Disclosed balance after: 2,484,425 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F3 · ownership.nature: Shares held by Cobro Ventures Opportunity Fund, L.P. ("Cobro Ventures"). The Reporting Person serves as a manager of Cobro Opportunity Fund GP, LLC, the general partner of Cobro Ventures, and may be deemed to exercise voting and investment power over the shares held by Cobro Ventures. The Reporting Person disclaims beneficial ownership of the shares held by Cobro Ventures except to the extent of his pecuniary interest therein. Read SEC document |
| October 06, 2020 Filed Oct 6, 2020 21:28 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | ConversionCommon Stock | 1,482,183 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-027697 · doc4.xml · nonDerivative · entry 2 COHEN MARC A · CIK 0001132945 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,852,207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F2 · ownership.nature: Shares held by Reporting Person as trustee of the Marc Andrew Cohen Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| October 06, 2020 Filed Oct 6, 2020 21:28 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | ConversionCommon Stock | 237,149 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-027697 · doc4.xml · nonDerivative · entry 1 COHEN MARC A · CIK 0001132945 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 370,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F2 · ownership.nature: Shares held by Reporting Person as trustee of the Marc Andrew Cohen Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 21:00 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 17,786 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027447 · doc4.xml · derivative · entry 2 COHEN MARC A · CIK 0001132945 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,786 Underlying: Common Stock · 17,786 shares Expires 2030-09-30 F2 · derivative.exercise_date: This option shall vest and become exercisable upon the earlier to occur of (i) October 1, 2021, and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 21:00 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 725,002 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027447 · doc4.xml · derivative · entry 1 COHEN MARC A · CIK 0001132945 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 725,002 Underlying: Common Stock · 725,002 shares Expires 2030-09-30 F1 · derivative.exercise_date: 12.5% of this option shall vest and become exercisable on April 1, 2021, with the remainder vesting in 14 equal quarterly installments thereafter. Read SEC document |
| June 11, 2020 Filed Jun 12, 2020 07:19 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 14,846 | $0.00 Strike: $18.63 | $0.00 |
DisclosureSEC source: 0001127602-20-019478 · form4.xml · derivative · entry 1 COHEN MARC A · CIK 0001132945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,846 Underlying: Common Stock · 14,846 shares Expires 2030-06-10 F1 · derivative.exercise_date: The option vests in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders. Read SEC document |
| January 30, 2020 Filed Feb 3, 2020 16:05 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionStock Option · Derivative | 20,778 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0000899243-20-002536 · doc4.xml · derivative · entry 11 COHEN MARC A · CIK 0001132945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,778 shares Expires 2029-04-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is fully vested. Read SEC document |
| January 30, 2020 Filed Feb 3, 2020 16:05 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionStock Option · Derivative | 20,778 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0000899243-20-002536 · doc4.xml · derivative · entry 10 COHEN MARC A · CIK 0001132945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,778 shares Expires 2029-04-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is fully vested. Read SEC document |
| January 30, 2020 Filed Feb 3, 2020 16:05 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionStock Option · Derivative | 21,827 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0000899243-20-002536 · doc4.xml · derivative · entry 9 COHEN MARC A · CIK 0001132945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,918 Underlying: Common Stock · 21,827 shares Expires 2029-04-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a two year period commencing on February 1, 2019, and will be fully vested and exercisable on January 1, 2021. Read SEC document |
| January 30, 2020 Filed Feb 3, 2020 16:05 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionStock Option · Derivative | 16,691 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0000899243-20-002536 · doc4.xml · derivative · entry 8 COHEN MARC A · CIK 0001132945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,072 Underlying: Common Stock · 16,691 shares Expires 2028-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2018, and will be fully vested and exercisable on January 1, 2022. Read SEC document |
| January 30, 2020 Filed Feb 3, 2020 16:05 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionStock Option · Derivative | 8,042 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0000899243-20-002536 · doc4.xml · derivative · entry 7 COHEN MARC A · CIK 0001132945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,063 Underlying: Common Stock · 8,042 shares Expires 2027-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2017, and will be fully vested and exercisable on January 1, 2021. Read SEC document |
| January 30, 2020 Filed Feb 3, 2020 16:05 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 20,778 | $3.37 | $70,021.86 |
DisclosureSEC source: 0000899243-20-002536 · doc4.xml · nonDerivative · entry 5 COHEN MARC A · CIK 0001132945 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Marc Andrew Cohen Revocable Trust Disclosed balance after: 605,820 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2020 Filed Feb 3, 2020 16:05 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 20,778 | $3.37 | $70,021.86 |
DisclosureSEC source: 0000899243-20-002536 · doc4.xml · nonDerivative · entry 4 COHEN MARC A · CIK 0001132945 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Marc Andrew Cohen Revocable Trust Disclosed balance after: 585,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2020 Filed Feb 3, 2020 16:05 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 21,827 | $3.37 | $73,556.99 |
DisclosureSEC source: 0000899243-20-002536 · doc4.xml · nonDerivative · entry 3 COHEN MARC A · CIK 0001132945 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Marc Andrew Cohen Revocable Trust Disclosed balance after: 564,264 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2020 Filed Feb 3, 2020 16:05 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 16,691 | $0.61 | $10,181.51 |
DisclosureSEC source: 0000899243-20-002536 · doc4.xml · nonDerivative · entry 2 COHEN MARC A · CIK 0001132945 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Marc Andrew Cohen Revocable Trust Disclosed balance after: 542,437 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2020 Filed Feb 3, 2020 16:05 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 8,042 | $0.61 | $4,905.62 |
DisclosureSEC source: 0000899243-20-002536 · doc4.xml · nonDerivative · entry 1 COHEN MARC A · CIK 0001132945 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Marc Andrew Cohen Revocable Trust Disclosed balance after: 525,746 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 15:00 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 20,778 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0000899243-19-028544 · doc4.xml · derivative · entry 1 COHEN MARC A · CIK 0001132945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,778 Underlying: Common Stock · 20,778 shares Expires 2029-04-16 F1 · derivative.exercise_date: The option is fully vested. Read SEC document |
| October 07, 2019 Filed Oct 8, 2019 20:31 UTC | Korro Bio, Inc. FREQ · Entity 6388 | ConversionSeries C Preferred Stock · Derivative | 163,388 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-025352 · doc4.xml · derivative · entry 5 COHEN MARC A · CIK 0001132945 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Marc Andrew Cohen Revocable Trust Disclosed balance after: 0 Underlying: Common Stock · 24,258 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis. F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis. Read SEC document |
| October 07, 2019 Filed Oct 8, 2019 20:31 UTC | Korro Bio, Inc. FREQ · Entity 6388 | ConversionSeries B Preferred Stock · Derivative | 543,219 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-025352 · doc4.xml · derivative · entry 4 COHEN MARC A · CIK 0001132945 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Marc Andrew Cohen Revocable Trust Disclosed balance after: 0 Underlying: Common Stock · 80,650 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis. F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis. Read SEC document |
| October 07, 2019 Filed Oct 8, 2019 20:31 UTC | Korro Bio, Inc. FREQ · Entity 6388 | ConversionSeries A Preferred Stock · Derivative | 2,292,235 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-025352 · doc4.xml · derivative · entry 3 COHEN MARC A · CIK 0001132945 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Marc Andrew Cohen Revocable Trust Disclosed balance after: 0 Underlying: Common Stock · 340,321 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis. F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis. Read SEC document |
| October 07, 2019 Filed Oct 8, 2019 20:31 UTC | Korro Bio, Inc. FREQ · Entity 6388 | PurchaseCommon Stock | 17,857 | $14.00 | $249,998.00 |
DisclosureSEC source: 0000899243-19-025352 · doc4.xml · nonDerivative · entry 2 COHEN MARC A · CIK 0001132945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,857 Read SEC document |
| October 07, 2019 Filed Oct 8, 2019 20:31 UTC | Korro Bio, Inc. FREQ · Entity 6388 | ConversionCommon Stock | 445,229 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-025352 · doc4.xml · nonDerivative · entry 1 COHEN MARC A · CIK 0001132945 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Marc Andrew Cohen Revocable Trust Disclosed balance after: 517,704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis. F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.